

31 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer's; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to *Scrip*.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 October 2021, including: [*Eli Lilly and Company*](#) goes head-to-head in Alzheimer's; [*Roche Holding AG*](#) eyes new opportunities for Lucentis; [*Novartis AG*](#) doubles down on innovation; [*Bristol Myers Squibb Company*](#) seeks growth amid generic threats; and the new head of [*Boehringer Ingelheim GmbH*](#) in India talks to *Scrip*.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer's*](#)" - *Scrip*, 26 Oct, 2021.)

(Also see "[*Roche's Port Delivery System Approved, Paving The Way For Ophthalmology Expansion*](#)" - *Scrip*, 22 Oct, 2021.)

(Also see "[*Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale*](#)" - *Scrip*, 26 Oct, 2021.)

(Also see "[*BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near*](#)" - *Scrip*, 27

Oct, 2021.)

(Also see "[*B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma*](#)" - Scrip, 27 Oct, 2021.)

[Click here to explore this interactive content online](#) 